Use of hmgb polypetides for increasing immune responses
The present invention features polypeptides comprising an HMGB B box or a functional variant thereof that are useful for stimulating or increasing an immune response in an individual. Such polypeptides can be used in vaccine formulations and in cancer therapies.
1 . A pharmaceutical composition comprising a polypeptide comprising an HMGB B box or a functional variant thereof, in an amount sufficient to treat a disease or condition by increasing an immune response in an individual administered said pharmaceutical composition.
2 . The pharmaceutical composition of claim 1 , wherein said HMGB B box is mammalian.
3 . The pharmaceutical composition of claim 2 , wherein said HMGB B box is human.
4 . The pharmaceutical composition of claim 3 , wherein said polypeptide comprises an HGB1 B box polypeptide.
5 . The pharmaceutical composition of claim 4 , wherein said polypeptide consists of an HMGB1 B box polypeptide.
6 . The pharmaceutical composition of claim 1 , further comprising a vaccine.
7 . The pharmaceutical composition of claim 6 , further comprising an adjuvant.
8 . The pharmaceutical composition of claim 7 , wherein said adjuvant is selected from the group consisting of one or more immunostimulatory oligonucleotides, an imidazoquinoline, monophosphoryl lipid A, Brad detoxified lipopolysaccharide.
9 . The pharmaceutical composition of claim 8 , wherein said immunostimulatory oligonucleotides comprise unmethylated CpG sequences.
10 . An antibody attached to a polypeptide comprising an HMGB B box or a functional variant there of.
11 . The antibody of claim 10 , wherein said HMGB B box is mammalian.
12 . The antibody of claim 11 , wherein said HMGB B box is human.
13 . The antibody of claim 12 , wherein said polypeptide comprises an HMGB1 B box polypeptide.
14 . The antibody of claim 13 , wherein said polypeptide consists of an HMGB1 B box polypeptide.
15 . The antibody of claim 10 , wherein said antibody binds a rumor-associated polypeptide.
16 . The antibody of claim 10 , wherein said antibody is in a pharmaceutically acceptable carrier.
17 . A method of simulating or increasing an immune response in an individual in need of immunostimulation, said method comprising administering to said individual a polypeptide comprising an HMGB B box or a functional variant thereof, in a amount sufficient to stimulate or increase said immune response.
18 . The method of claim 17 , wherein said individual is being treated for cancer.
19 . The method of claim 17 , wherein said HMGB B box is mammalian.
20 . The method of claim 19 , wherein said HMGB B box is human.
21 . The method of claim 20 , wherein said polypeptide comprises an HMGB1 B box.
22 . The method of claim 21 , wherein said polypeptide consists of an HMGB1 B box.
23 . The method of claim 17 , wherein said polypeptide is co-administered with a vaccine.
24 . The method of claim 23 , wherein said polypeptide is co-administered with a m further adjuvant.
25 . The method of claim 24 , wherein said adjuvant is selected from the group consisting of one or more immunostimulatory oligoneucleotides, an imidazoquinoline, monophosphoryl lipid A, and detoxified W lipopolysaccharide.
26 . The method of claim 25 , wherein said immunostimulatory oligonucleotides comprise unmethylated CpG sequences.
27 . The method of claim 17 , wherein said administration is systemic.
28 . The method of claim 17 , wherein said administration is localized to a target site.
29 . The method of claim 17 , wherein said polypeptide is attached to an antibody specific to a target site in the individual in need of immunostimulation.
30 . The method of claim 17 , wherein said polypeptide is in a pharmaceutically acceptable carrier.
31 . A method of treating cancer in an individual, said method comprising administering to said individual a therapeutically effective amount of a polypeptide comprising an HMGB B box or a functional variant thereof.
32 . The method of claim 31 , wherein said HMGB B box is mammalian.
33 . The method of claim 32 , wherein said HMGB B box is human.
34 . The method of claim 33 , wherein said polypeptide comprises an HMGB1 B box polypeptide.
35 . The method of claim 34 , wherein said polypeptide consists of an HMGB1 B box polypeptide.
36 . The method of claim 31 , wherein said polypeptide is co-administered with a vaccine.
37 . The method of claim 36 , wherein said polypeptide is co-administered with a further adjuvant.
38 . The method of claim 37 , wherein said adjuvant is selected from the group consisting of one or more immunostimulatory oligonucleotides, an imidazoquinoline monophosphoryl lipid A, and detoxified lipopolysacharide.
39 . The method of claim 38 , wherein said immunostimulatory oligonucleotides comprise unmethylated CpG sequences.
40 . The method of claim 31 , wherein said administration is systemic.
41 . The method of claim 31 , wherein said administration is localized to a target site.
42 . The method of claim 41 , wherein said target site is a tumor.
43 . The method of claim 31 , wherein said polypeptide is attached to an antibody.
44 . The method of claim 43 , wherein said antibody binds a tumor-associated polypeptide.
45 . The method of claim 31 , wherein said polypeptide is in a pharmaceutically acceptable carrier.